Cabotegravir Injection

DRUG3 trials

Sponsors

Evandro Chagas National Institute of Infectious Disease, Oregon Health and Science University, Duke University

Conditions

HIV InfectionsHIV/AIDSIncarceration; LensOpioid Use Disorder

Phase 3

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir

RecruitingNCT05515770

Evandro Chagas National Institute of Infectious DiseaseHIV Infections

Start: 2022-09-20End: 2026-02-28Target: 1200Updated: 2024-10-08

Phase 4

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

Not yet recruitingNCT06854029

Duke UniversityHIV Infections, Incarceration; Lens, Opioid Use Disorder

Start: 2026-09-01End: 2030-06-01Target: 450Updated: 2026-08-26

Unknown Phase

Oregon PrEP at Home Study

Oregon Health and Science UniversityHIV/AIDS

Start: 2023-12-01End: 2025-12-01Target: 125Updated: 2023-12-06

Related Papers

Exploring perceptions and preferences for PrEP choice and of an mHealth intervention: insights from the ImPrEP CAB‐Brasil study

Journal of the International AIDS Society2025-07-012 citations

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study

JMIR Public Health and Surveillance2023-04-1912 citations